Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of ES104 for Treatment of Colorectal Cancer
SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)--#CRCSM--Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and...







